SVR rates in the PRESCO trial
0
10
20
30
40
50
60
70
80
90
48 weeks
72 weeks
24 weeks
48 weeks
31
53
67
82
59/192
HCV GT 1/4 (n=237)
HCV GT 2/3 (n=152)
SVR (% patients)
                    15 (8%)                  36 (80%)                          4 (4%)            9 (16%)
Discontinuations
due to patient wish:
24/45
64/96
46/56
100
Nunez M et al. ICAAC 2006